S-1/A: Shoulder Innovations Files for IPO Amid Rapid Revenue Growth and Expanding Losses, Securing $40M Convertible Note

Shoulder Innovations, a commercial-stage medical technology company focused on shoulder surgical care, is pursuing an initial public offering of 5 million shares to fund its rapid growth, despite reporting increasing net losses and significant operating expenses.

Summary

• Shoulder Innovations is offering 5,000,000 shares of common stock in its initial public offering, with an anticipated price range of $19.00 to $21.00 per share, and plans to list on the New York Stock Exchange under the symbol SI.
• The company generated net revenue of $31.6 million for the year ended December 31, 2024, representing 64.0% year-over-year growth from $19.3 million in 2023.
• For the three months ended March 31, 2025, net revenue increased by 41.0% to $10.1 million, compared to $7.2 million for the same period in 2024.
• Preliminary estimated net revenue for the three months ended June 30, 2025, is between $10.8 million and $11.2 million, an increase from $8.3 million in the prior year period.
• The company reported a net loss of $15.6 million for the year ended December 31, 2024, an increase from $12.7 million in 2023.
• Net loss for the three months ended March 31, 2025, was $4.7 million, up from $3.6 million in the prior year period.
• Preliminary estimated net loss for the three months ended June 30, 2025, is significantly higher, ranging from $19.1 million to $21.1 million, compared to $4.2 million in the prior year period, primarily due to non-cash charges related to warrant liability and Series E purchase option.
• Gross margin for FY 2024 was 77.0%, a slight decrease from 79.2% in FY 2023, primarily due to inventory adjustments.
• Adjusted EBITDA loss increased to $11.4 million for FY 2024 from $8.7 million for FY 2023.
• As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $27.6 million, with an expected balance of $39.6 million as of June 30, 2025.
• The company had an accumulated deficit of $61.7 million as of March 31, 2025.
• Shoulder Innovations issued $40.0 million in convertible promissory notes on July 18, 2025, which will automatically convert into common stock upon the IPO completion.
• The company's InSet Glenoid technology has demonstrated a 72-point improvement in mean ASES outcome score and no surgical complications, glenoid loosening, or revision surgeries at a mean follow-up of 8.7 years in a published study.
• ProVoyance preoperative planning technology, which integrates AI and ML, had an implied utilization rate of approximately 98% for the three months ended June 30, 2025.
• The company's efficient two-tray instrument system supports both anatomic and reverse total shoulder arthroplasty procedures, significantly reducing operating room footprint and sterilization requirements compared to typical 6-9 tray systems.
• Total shoulder arthroplasty was approved for Medicare reimbursement in Ambulatory Surgery Centers (ASCs) effective January 1, 2024, which is expected to further support growth in outpatient settings.
• The number of ASC-based procedures using the company's systems increased approximately 350% from 2023 to 2024, significantly outpacing the overall ASC-based shoulder arthroplasty market growth of 26%.

Sentiment

Score: 6

Explanation: The company demonstrates strong revenue growth and innovative product development with positive clinical outcomes, particularly in the growing ASC market. However, significant and increasing net losses, reliance on single-source suppliers, and ongoing litigation present notable financial and operational risks. The IPO and recent convertible note issuance address immediate capital needs but highlight a continued reliance on external funding for future operations and growth, leading to substantial dilution for new investors.

Positives

• Experienced significant net revenue growth: 64.0% year-over-year in FY 2024 ($31.6M from $19.3M) and 41.0% in Q1 2025 ($10.1M from $7.2M).
• Strong preliminary estimated net revenue growth for Q2 2025 ($10.8M-$11.2M vs. $8.3M in Q2 2024) and H1 2025 ($20.9M-$21.3M vs. $15.4M in H1 2024).
• High utilization rate of ProVoyance AI/ML-enabled preoperative planning technology (approximately 98% in Q2 2025), indicating strong surgeon adoption and value proposition.
• Robust product pipeline with anticipated expansion of humeral stem line, indication expansions into fracture and revision, and implants for metal-sensitive patients, demonstrating commitment to innovation.
• Strong clinical evidence supporting InSet Glenoid technology, showing significant improvements in ASES outcome scores (72-point improvement), pain reduction, and no reported surgical complications, glenoid loosening, or revision surgeries at 8.7 years mean follow-up.
• Well-positioned to capitalize on the shift to outpatient and Ambulatory Surgery Center (ASC) settings, with ASC-based procedures using its systems increasing approximately 350% from 2023 to 2024.
• Efficient two-tray instrument system offers significant workflow advantages, reducing operating room footprint, setup time, and sterilization costs, which is highly beneficial for ASCs.
• Experienced management team with decades of orthopedic product development and commercialization experience, holding over 250 combined orthopedic patents.
• Dedicated commercial organization with specialized shoulder expertise and a network of independent distributors, fostering strong surgeon relationships and driving adoption.

Negatives

• History of significant net losses, with an accumulated deficit of $61.7 million as of March 31, 2025, and expectation to incur additional substantial losses in the foreseeable future.
• Net loss increased to $15.6 million in FY 2024 from $12.7 million in FY 2023, and to $4.7 million in Q1 2025 from $3.6 million in Q1 2024.
• Preliminary estimated net loss for Q2 2025 is significantly higher, ranging from $19.1 million to $21.1 million, compared to $4.2 million in Q2 2024, primarily due to non-cash charges.
• Adjusted EBITDA loss increased to $11.4 million in FY 2024 from $8.7 million in FY 2023, and preliminary estimates for Q2 2025 show a substantial increase in Adjusted EBITDA loss to $18.0M-$20.0M.
• Gross margin slightly decreased to 77.0% in FY 2024 from 79.2% in FY 2023, primarily due to inventory adjustments.
• Significant amount of debt, with $15.0 million principal outstanding under the Trinity Loan Agreement as of March 31, 2025, and an additional $40.0 million in convertible notes issued in July 2025.
• Reliance on certain assumptions about the addressable market size and growth, which may prove incorrect, potentially leading to smaller market share capture than estimated.
• Heavy dependence on third-party contract manufacturers and suppliers, with the majority being single-source, posing supply chain risks and potential delays if issues arise.
• Existence of related-party transactions and affiliations between officers/directors and key business partners (Genesis Innovation, Genesis Software, cultivate(MD)), which may give rise to perceived or actual conflicts of interest.

Risks

• The company is an early-stage company with a history of significant net losses and expects to incur operating losses in the future, potentially failing to achieve or sustain profitability.
• Failure to manage rapid growth effectively could materially and adversely affect the business.
• The company has a significant amount of debt, which may affect its ability to operate and secure additional financing, and covenants may restrict business activities.
• Substantial additional funding may be required in the future, which may not be available on acceptable terms or at all, potentially delaying or ceasing innovation efforts or operations.
• Operating in a very competitive business environment, with larger, more resourced competitors, could adversely affect business, financial condition, and results of operations.
• Failure to develop and retain an effective dedicated commercial organization or expand it successfully could negatively impact sales and profitability.
• Business plan relies on assumptions about the market for implant systems, but the size and expected growth of the addressable market may be smaller than estimated, or the company may fail to capture additional market share.
• Business is dependent upon the adoption of implant systems by hospitals, ASCs, surgeons, and patients, which may be slow or limited.
• Long-term growth depends on the ability to enhance implant systems, expand indications, and develop and commercialize additional products in a timely manner; failure to innovate could lead to obsolescence.
• Risk of product liability claims that could be expensive, divert management's attention, harm reputation, and potentially exceed insurance coverage.
• Industry trends have resulted in increased downward pricing pressure on medical services and products, which may affect the ability to sell products at necessary prices.
• If hospitals, ASCs, and other healthcare facilities do not approve the use of implant systems, sales may not increase.
• Dependence on third-party contract manufacturers and suppliers, some of which are single-source, poses risks of supply interruptions, quality issues, and increased costs.
• Inability to accurately forecast demand for implant systems and manage inventory could materially harm results of operations.
• Difficulty in successfully demonstrating the merits of implant systems and technologies to shoulder specialists or key opinion leaders compared to competitors could hinder market acceptance.
• Loss of any executive management team member or inability to attract and retain highly skilled personnel could have a material adverse effect.
• Conflicts of interest may arise due to certain officers and directors serving as directors of, and being affiliated with, Genesis Innovation, Genesis Software, and cultivate(MD).
• Inability to obtain and maintain significant patent or other intellectual property protection, or if the scope of intellectual property rights is inadequate, competitors could commercialize similar products.
• Devices and operations are subject to extensive government regulation and oversight in the United States; failure to comply could result in enforcement actions.
• Relationships with customers, physicians, and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and physician payment transparency laws; violations could lead to substantial penalties.
• Misuse or off-label use of systems may result in injuries, harm reputation, or lead to costly investigations, fines, or sanctions.
• Implant systems may cause or contribute to adverse medical events or be subject to failures/malfunctions requiring FDA reporting, potentially leading to recalls or sanctions.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, staffing limitations) could hinder timely product review and commercialization.
• Subject to stringent and evolving U.S. and foreign laws, regulations, and rules related to data privacy and security, with potential for adverse consequences from non-compliance or breaches.
• The market price of common stock may be volatile, potentially resulting in substantial losses for investors.
• Investors in this offering will experience immediate and substantial dilution.
• Principal stockholders and management own a significant percentage of stock and can exert significant control over stockholder approval matters.
• Sales of a substantial number of shares in the public market could cause the stock price to fall.
• Provisions in charter documents and Delaware law could discourage a takeover.
• No intention to pay dividends in the foreseeable future; return on investment depends on stock price appreciation.
• Increased costs and additional regulations as a public company could lower profits or make business more difficult.
• Inability to design, implement, and maintain effective internal control over financial reporting could lead to loss of investor confidence.
• Insurance may not cover all potential losses or liabilities.
• Subject to U.S. anti-bribery, anti-corruption, and anti-money laundering laws, as well as export control, customs laws, and economic sanctions.
• Adverse effects from natural disasters and other catastrophic events on operations or third-party dependencies.
• Risks from legal and arbitration proceedings, including a patent infringement lawsuit with Catalyst OrthoScience Inc., which could incur additional costs or damages.
• Requirements of being a public company may divert management's attention from growth strategies.
• If securities or industry analysts do not publish research or issue adverse opinions, stock price and trading volume could decline.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Changes in tax laws or regulations or their interpretation could seriously harm the business.
• Increasing use of social media platforms presents new risks and challenges.

Future Outlook

The company anticipates continued long-term revenue growth driven by expanding its commercial organization, adding new customers, increasing sales territories, and introducing new products. It plans to strategically pursue entry into international markets over time. Significant investments in product development are expected, including new humeral stems, fracture-specific systems, revision solutions, and implants for metal-sensitive patients, with anticipated FDA clearances for some stems within the next twelve months. The company is also evaluating expansion into adjacent shoulder surgical care areas like sports medicine and trauma, and assessing robotic-assisted technology implementation. It expects continued focus on increasing awareness and adoption of its ecosystem, particularly in outpatient and ASC settings, which are seen as key growth drivers.

Management Comments

• Our exclusive focus on shoulder surgical care, combined with a highly specialized commercial organization and strong clinical data, positions us well to capture significant share in this large, growing market.
• We believe the shoulder surgical care market today presents a significant market opportunity.
• We developed our ecosystem with an approach to innovation that prioritizes ease of use, flexibility, predictability of outcomes and site of care efficiency, attributes we believe are critical to win in our market.
• We believe the differentiation and value proposition of ProVoyance is validated by high utilization rates across procedures using our advanced implant systems.
• We leverage our team's decades of experience developing and launching novel shoulder surgical care technologies to identify the unmet needs of patients and surgeons and develop solutions to address those unmet needs.
• We are committed to continued investment in obtaining further clinical evidence with the support of surgeons who are recognized as thought leaders in shoulder surgical care.
• Our goal is to leverage our purpose-built ecosystem to become the leader for shoulder surgical care.
• We view ourselves as specialists serving specialists, having purposefully built our commercial organization around the unique needs of shoulder surgeons.
• We believe this outsourcing strategy provides the expertise and capacity required to effectively and efficiently scale production based on demand, and helps to ensure low-cost production and a capital efficient business model.
• We believe outpatient and ASC settings represent an important and growing opportunity to drive demand and net revenue.
• We anticipate we will continue to invest significantly in product development, including with respect to our supporting technologies, in order to further bolster our ecosystem.
• We believe this continued commitment to innovation will further expand our addressable market opportunity and improve our competitive position in shoulder surgical care.
• We believe our current network of third-party manufacturing and supply providers provides for sufficient capacity to meet projected market demand for our products for the foreseeable future.
• We believe we have established a compelling value proposition to compete favorably in this market.

Industry Context

The company operates in the shoulder surgical care market, specifically focusing on shoulder arthroplasty, which is a large ($1.7 billion in the U.S. in 2025, $2.8 billion globally) and rapidly growing segment within orthopedic reconstruction (estimated 11% annual growth through 2029). A significant industry trend is the shift of surgical procedures to outpatient settings, particularly Ambulatory Surgery Centers (ASCs), driven by lower costs and increased efficiency. The company is well-positioned to benefit from this trend, with its efficient two-tray instrument system and the recent CMS approval for total shoulder arthroplasty reimbursement in ASCs. The market is highly competitive, with large multinational players like Arthrex, Johnson & Johnson, Smith & Nephew, Stryker, and Zimmer Biomet, as well as smaller innovators. The company differentiates itself through its specialized focus, AI/ML-enabled preoperative planning (ProVoyance), and strong clinical evidence supporting its InSet Glenoid technology.

Comparison to Industry Standards

• The company's efficient two-tray instrument system is considerably less than the six to nine trays typically required by other offerings in shoulder arthroplasty, providing significant workflow advantages and cost reductions for healthcare providers, especially in ASC settings.
• The InSet Glenoid technology demonstrated an 87% reduction in 'rocking horse motion' in a finite element analysis, a key contributor to implant loosening and failure in traditional aTSA implants, suggesting superior biomechanical design compared to legacy systems.
• Clinical data for the InSet Glenoid showed no surgical complications, cases of glenoid loosening, or revision surgeries at a mean follow-up of 8.7 years, which is a strong indicator of longevity and stability compared to industry averages where glenoid loosening is a common issue (e.g., 30% of implants showing moderate to severe loosening within 6.6 years and up to 40% requiring revision within ten years for traditional aTSA).
• The company's ASC-based procedures increased approximately 350% from 2023 to 2024, significantly outpacing the approximately 26% growth in ASC-based shoulder arthroplasty procedures in the United States over the same period, indicating strong market penetration and alignment with evolving care dynamics.
• The company's ProVoyance technology's implied utilization rate of approximately 98% for Q2 2025 suggests a higher level of surgeon engagement in preoperative planning compared to other solutions where planning is often outsourced or less intuitive.

Management Changes

Corporate Governance

Legal Proceedings

• On February 28, 2024, the company filed a patent infringement complaint against Catalyst Orthoscience Inc. (Catalyst) in the United States District Court for the District of Delaware, alleging infringement of its patents related to reverse shoulder systems.
• Catalyst filed a counterclaim alleging patent infringement of its own patent by certain of the company's products.
• The company believes it has substantial and meritorious defenses to Catalyst's counterclaim and intends to vigorously defend its position.
• The outcome of the litigation is uncertain, and an adverse judgment or settlement could have a material adverse effect on the company's business, financial position, results of operations, or cash flows.

Related Party Transactions

• The company issued and sold $6.9 million in convertible promissory notes from September to November 2022 to investors, including entities affiliated with U.S. Venture Partners, Lightstone Ventures, cultivate(MD) Capital Accelerator Fund, L.P., Robert Ball (CEO), Paul Buckman (Director), and Kevin Sidow (Director). These notes converted into Series D preferred stock in February 2023.
• In February and March 2023, the company issued and sold 80,909,169 shares of Series D convertible preferred stock for approximately $43.8 million, including conversions of prior notes. Purchasers included Coperatieve Gilde Healthcare V U.A., entities affiliated with U.S. Venture Partners, Lightstone Ventures, and Gilmartin Capital Fund I L.P.
• In March and June 2025, the company issued and sold 58,774,312 shares of Series E convertible preferred stock for approximately $40.1 million. Purchasers included Coperatieve Gilde Healthcare V U.A., entities affiliated with U.S. Venture Partners, Gilmartin Capital Fund I L.P., Arboretum Ventures VI, LP, Robert Ball (CEO), and The David Lawrence Blue Living Trust (affiliated with David L. Blue, Chief Customer Experience Officer).
• In February 2025, Genesis Investment Holdings, LLC, an entity affiliated with cultivate(MD), exercised a Series Seed preferred stock warrant for approximately $0.2 million.
• The company has a consulting agreement with Genesis Innovation Group, Inc., an entity co-founded and directed by Robert Ball (CEO). Payments to Genesis Innovation were $3.6 million in 2024, $2.8 million in 2023, and $1.2 million in Q1 2025.
• The company has a software license agreement with Genesis Software Innovations, LLC, where Robert Ball (CEO) is a co-founder and director, and Matthew Ahearn (COO) is a director of an affiliated entity. Payments to Genesis Software were $3.1 million in 2024, $3.2 million in 2023, and $0.9 million in Q1 2025, including royalties.
• The company entered into a supply agreement with Revelation Medical Devices (RMD) on June 3, 2024. Robert Ball (CEO) was an investor in RMD during 2024. Payments to RMD were $0.9 million in 2024 and $2.3 million in 2023. No payments were made in Q1 2025.
• Certain directors and officers (Matthew Ahearn, Robert Ball, David L. Blue, Michael Carusi, Geoff Pardo, Casey Tansey) are associated with principal stockholders (cultivate(MD), Lightstone Ventures, Coperatieve Gilde Healthcare V U.A., U.S. Venture Partners).

Stakeholder Impact

• **Shareholders (Existing & New)**: Existing shareholders will experience immediate and substantial dilution from the IPO. New investors will also face dilution. The concentration of ownership by principal stockholders and management (57.1% post-IPO) means they can exert significant control over company matters. Future profitability and stock appreciation are key for investor returns, as no dividends are planned.
• **Employees**: The IPO and capital raise are intended to scale the commercial organization through additional hires, offering growth opportunities. Equity incentive plans (2025 Plan, ESPP) are designed to attract, retain, and motivate employees. However, the company's at-will employment policy and competition for skilled personnel pose risks.
• **Customers (Hospitals, ASCs, Surgeons)**: The company's focus on ease of use, efficiency (two-tray system), and predictable outcomes aims to provide significant benefits, including reduced operating room footprint and costs. Continued innovation and specialized support are designed to enhance customer satisfaction and adoption. However, pricing pressures and potential issues with third-party suppliers could impact product availability and cost.
• **Suppliers**: The company relies heavily on single-source third-party manufacturers and suppliers. Any disruptions or failures by these suppliers could materially affect the company's ability to meet demand, potentially impacting supplier relationships.
• **Creditors**: The company has significant debt, including the Trinity Loan Agreement and new convertible notes. Its ability to service this debt depends on generating sufficient cash flow from operations, which is currently negative. Defaulting on debt covenants could lead to immediate repayment demands and foreclosure on assets.

Next Steps

• Complete the Initial Public Offering of 5,000,000 shares of common stock and list on the New York Stock Exchange under the symbol SI.
• Scale up the commercial organization through hiring additional sales representatives and expanding the commercial leadership team.
• Invest in additional instrument sets to support volume growth and geographic expansion.
• Fund research and development for continued general innovation in implant systems.
• Pursue FDA clearance for new humeral stems (InSet 70, InSet 135, InSet 185) over the next twelve months.
• Pursue FDA clearance for humeral head and glenoid technologies for metal-sensitive patients over the next twelve months.
• Evaluate expansion into adjacent areas in shoulder surgical care, including sports medicine and shoulder trauma markets.
• Assess the implementation of robotic-assisted technology for implant systems.
• Continue building and driving marketing of technology solutions, including leveraging the internal business intelligence platform and ProVoyance.
• Pursue strategic entry into attractive, high-growth international markets.
• Continue to invest in obtaining further clinical evidence and expect the first publication of the patient registry as early as 2026.
• Vigorously defend against the patent infringement counterclaim filed by Catalyst Orthoscience Inc.

Key Dates

Recommendation

Shoulder Innovations presents a compelling growth story in a rapidly expanding market, driven by innovative products, strong clinical data, and a strategic focus on the high-growth ASC segment. The company's revenue growth is impressive, and its AI-enabled planning technology shows high adoption. However, the company is currently unprofitable, with significant and increasing net losses, particularly in the most recent preliminary estimates, indicating a high cash burn rate. The substantial debt and reliance on single-source suppliers introduce considerable risk. While the IPO provides necessary capital for expansion, the immediate and substantial dilution for new investors, coupled with the company's early stage and competitive landscape, suggests a 'hold' recommendation. Investors should monitor the company's ability to translate its strong product adoption and market positioning into sustainable profitability and effective management of its supply chain and financial leverage before considering a 'buy' position.

Keywords

Shoulder Arthroplasty, Medical Technology, Orthopedic Implants, IPO, S-1/A, SEC Filing, ProVoyance, AI/ML Medical Devices, InSet Glenoid, Humeral Stem, Ambulatory Surgery Centers (ASCs), Healthcare Innovation, Surgical Instruments, FDA Clearance, Clinical Data, Patent Litigation, Convertible Notes, Net Loss, Revenue Growth